These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33187107)

  • 21. Emerging Insights into Mu Opioid Pharmacology.
    Pasternak GW; Childers SR; Pan YX
    Handb Exp Pharmacol; 2020; 258():89-125. PubMed ID: 31598835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
    Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
    Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delineation of the functional properties and the mechanism of action of AA29504, an allosteric agonist and positive allosteric modulator of GABA
    Olander ER; Madjroh N; Bunch L; Söderhielm PC; Jensen AA
    Biochem Pharmacol; 2018 Apr; 150():305-319. PubMed ID: 29454619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel GPCR paradigms at the μ-opioid receptor.
    Thompson GL; Kelly E; Christopoulos A; Canals M
    Br J Pharmacol; 2015 Jan; 172(2):287-96. PubMed ID: 24460711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism.
    Henderson-Redmond AN; Yuill MB; Lowe TE; Kline AM; Zee ML; Guindon J; Morgan DJ
    Brain Res Bull; 2016 May; 123():5-12. PubMed ID: 26521067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical opioids differentially induce co-internalization of μ- and δ-opioid receptors.
    Bao F; Li CL; Chen XQ; Lu YJ; Bao L; Zhang X
    Mol Pain; 2018; 14():1744806918769492. PubMed ID: 29587571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABA
    Lewter LA; Fisher JL; Siemian JN; Methuku KR; Poe MM; Cook JM; Li JX
    ACS Chem Neurosci; 2017 Jun; 8(6):1305-1312. PubMed ID: 28150939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanisms of allosteric probe dependence in μ opioid receptor.
    Bartuzi D; Kaczor AA; Matosiuk D
    J Biomol Struct Dyn; 2019 Jan; 37(1):36-47. PubMed ID: 29241414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
    Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
    Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interplay between Two Allosteric Sites and Their Influence on Agonist Binding in Human μ Opioid Receptor.
    Bartuzi D; Kaczor AA; Matosiuk D
    J Chem Inf Model; 2016 Mar; 56(3):563-70. PubMed ID: 26863088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current strategies toward safer mu opioid receptor drugs for pain management.
    Ehrlich AT; Kieffer BL; Darcq E
    Expert Opin Ther Targets; 2019 Apr; 23(4):315-326. PubMed ID: 30802415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists.
    Gallantine EL; Meert TF
    Pharmacol Biochem Behav; 2004 Sep; 79(1):125-35. PubMed ID: 15388292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
    Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
    Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist.
    Mada S; Gerak LR; Soyer A; Maguire DR; Hu Z; Minervini V; Cunningham CW; France CP
    Psychopharmacology (Berl); 2020 Dec; 237(12):3591-3602. PubMed ID: 32820390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2.
    Ozaki S; Narita M; Narita M; Iino M; Miyoshi K; Suzuki T
    Neuroscience; 2003; 116(1):89-97. PubMed ID: 12535942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors.
    Shang Y; Yeatman HR; Provasi D; Alt A; Christopoulos A; Canals M; Filizola M
    ACS Chem Biol; 2016 May; 11(5):1220-9. PubMed ID: 26841170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
    Burford NT; Watson J; Bertekap R; Alt A
    Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.